Xenon Pharmaceuticals Inc.

Form 3

February 09, 2016

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:

3235-0104

Expires:

response...

January 31, 2005

0.5

Estimated average burden hours per

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting 2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol Person * Statement Xenon Pharmaceuticals Inc. [XENE] EMPFIELD JAMES R. (Month/Day/Year) 02/08/2016 (Last) (First) (Middle) 4. Relationship of Reporting 5. If Amendment, Date Original Person(s) to Issuer Filed(Month/Day/Year) C/O XENON (Check all applicable) **PHARMACEUTICALS** INC.. 200 - 3650 GILMORE 10% Owner Director WAY _X__ Officer Other (give title below) (specify below) (Street) 6. Individual or Joint/Group SVP, Drug Discovery Filing(Check Applicable Line) _X_ Form filed by One Reporting Person BURNABY, A1Â V5G 4W8 Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned 2. Amount of Securities 4. Nature of Indirect Beneficial 1. Title of Security Beneficially Owned Ownership Ownership (Instr. 4) (Instr. 4) Form: (Instr. 5) Direct (D) or Indirect (Instr. 5) Â 0 $D^{(1)}$ No securities are beneficially owned Reminder: Report on a separate line for each class of securities beneficially SEC 1473 (7-02) owned directly or indirectly. Persons who respond to the collection of information contained in this form are not

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

required to respond unless the form displays a

currently valid OMB control number.

1. Title of Derivative Security
2. Date Exercisable and Securities Underlying Conversion Ownership

(Instr. 4)
Expiration Date (Month/Day/Year)
Derivative Security

2. Date Exercisable and Securities Underlying Ownership Ownership
Derivative Security
Ownership
Ownership
Ownership
(Instr. 5)

Edgar Filing: Xenon Pharmaceuticals Inc. - Form 3

	Date Exercisable	Expiration Date	(Instr. 4) Title	Amount or Number of Shares	Price of Derivative Security	Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	
No securities are	(1)	(1)	N/A (1)	<u>(1)</u>	\$ 0	D	Â

Reporting Owners

Reporting Owner Name / Address			Relationships		
.	Director	10% Owner	Officer	Other	
EMPFIELD JAMES R.					
C/O XENON PHARMACEUTICALS INC.	â	Â	SVP, Drug Discovery	Â	
200 - 3650 GILMORE WAY	А	A	A SVP, Diug Discovery	A	
BURNABY. A1 V5G 4W8					

Signatures

/s/ Joanne Smartt,
Attorney-in-fact

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Not applicable

Â

Remarks:

Exhibit Index: 24.1 Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2